The Stanford spinout has gone public following a $238m IPO, after revealing that the university was also among the series B investors.

Karolinska Development-backed Biosergen has begun trading on the Nasdaq First Growth Market, having already undertaken a $5.9m offering earlier this month.

University of Oxford and OSI are set to exit the medical diagnostics software provider in a flotation with a $75m placeholder target.

The cancer therapy developer and Jackson Laboratory spinout floated at the upper end of its range and now has a $600m market cap.

Broad Institute and UPenn-linked cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

The oncology therapy developer has filed for an IPO just two years after emerging from stealth to advance Harvard and Stanford research.

Centessa, formed earlier this year through a ten-way merger involving multiple spinouts, has completed a listing in the US.

The Lund research-based oat milk brand has floated in a $1.43bn IPO on the Nasdaq Global Select Market after pricing shares at $17.

SUNY Polytechnic University-backed Norsk Titanium has begun trading on Euronext Growth Oslo.

Yale's immunological disease treatment developer floated its shares below its initial price range in an IPO in the US.